NCT02873936: A reported trial by Gilead Sciences
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02873936 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 27, 2016 |
| Completion date | March 20, 2018 |
| Required reporting date | March 20, 2021, midnight |
| Actual reporting date | Dec. 21, 2020 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |